This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Homepage Banner

Latest resources

View more
Real World Experience
Practical insights into the experiences of clinicians implementing treatment with EYLEA® (aflibercept) 8 mg in the UK
PP-EYL-GB-3143, April 2026
Suspecting ATTR-CM
Beyonttra®▼ (acoramidis) | Resources to support recognition of the 'red flags'
PP-BEY-GB-0243, April 2026
Ophthalmology Patient Support Materials
Access our range of downloadable patient support booklets and other resources
PP-EYL-GB-3117, March 2026
Ophthalmology Resources
Access useful, downloadable ophthalmology resources
PP-EYL-GB-3081, March 2026

Events & webinars

View more
BNMS 2024
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
PP-XOF-GB-0598, January 2025
ATTR-CM & Carpal Tunnel Syndrome
Beyonttra®▼ (acoramidis) | Early diagnosis of ATTR-CM using carpal tunnel biopsies
PP-BEY-GB-0226, March 2026
CV Summit 2025 - Highlights
Register Your Interest for 2026 Here
PP-BEY-GB-0007, November 2025
Cultural Inequalities In Contraception Services
Hear from Dr Radhika Vohra on how best to support your patients requiring contraception
PP-PF-WHC-IUS-GB-0113, March 2025

Learning Zone

View more
Request An Interactive Pharmacist’s Guide
NUBEQA® (darolutamide)
PP-NUB-GB-2388, May 2025
NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide
PP-NUB-GB-2129, March 2025
Urogenital Symptoms and Sexual Difficulties
(5 mins) Often underreported and undertreated symptoms that significantly affect a woman's relationships.
PP-PF-WHC-IUS-GB-0085 October 2024
Musculoskeletal Symptoms, Anxiety, Low Mood and Brain Fog
(4 mins) Causes for musculoskeletal (MSK) symptoms, how menopause can worsen existing anxiety and depression.
PP-PF-WHC-IUS-GB-0084 October 2024

Podcasts

View more
Conversations at ESMO 2025
NUBEQA® (darolutamide)
PP-NUB-GB-2752, March 2026
Conversations at ESMO 2025
NUBEQA® (darolutamide)
PP-NUB-GB-2751, March 2026
ESMO 2025
NUBEQA® (darolutamide)
PP-NUB-GB-2700, October 2025
The Macular Minute: Podcast Series
Your source for quick expert insights in medical retina
PP-EYL-GB-3090, March 2026

Products

View more
Angeliq® (1mg estradiol hemihydrate and 2mg drospirenone)
Introduction to Angeliq
PP-ANG-GB-0012, March 2026
NUBEQA® (darolutamide)
About NUBEQA
PP-NUB-GB-2950, March 2026
Beyonttra®▼ (acoramidis) - Overview
About Beyonttra
PP-BEY-GB-0213, March 2026
EYLEA® (aflibercept) 2 mg
Discover data and resources about EYLEA 2 mg
PP-EYL-GB-2793, March 2025

Register with BayerPRO

To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.